



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DC-0230
Inventors: Mulligan-Kehoe, Mary Jo
Serial No.: 10/686,428
Filing Date: October 14, 2003
Examiner: Huynh, Phuong N.
Customer No.: 26259
Group Art Unit: 1644
Confirmation No.: 1865
Title: Methods for Modulating Angiogenesis

"Express Mail" Label No.: EV583917499US

Date of Deposit: December 22, 2005

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Mail Stop Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By: Jane Massey Licata
Typed Name: Jane Massey Licata, Reg. No. 32,257

Mail Stop Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

RULE 132 DECLARATION

1. I, Dr. Mary Jo Mulligan-Kehoe, Ph.D. am the inventor in U.S. Patent Application Serial No. 10/686,428 filed October 14, 2003 and am most familiar with the subject matter of this application and the research effort which lead to the discovery of the instant invention.


2. As described in Example 1 of the '428 application, the DNA encoding the truncated PAI-1₂₃ protein was obtained by PCR amplifying a fragment of the porcine PAI-1 gene (poPAI-1) based on the poPAI-1 sequences that correspond to the human PAI-1 gene.

BEST AVAILABLE COPY

Attorney Docket No.: 1340-1-021CIP2 (SJ-0015)
Inventors: Sorrentino et al.
Serial No.: 09/866,866
Filing Date: May 29, 2001
Page 2

(huPAI-1). Amplification of the truncated porcine PAI-1₂₃ protein was carried out using the primers described in Mulligan-Kehoe et al. (2001) *J. Biol. Chem.* 276:8588-8596. As presented in paragraph one, column 2, of page 8589 of this reference, the primers were 5'-primer, 5'-GGAATTCAAGGAGCTATGG-3' and 3'-primer, 5'-GCTCTAGATTTCCACTGGTGATG-3'. As disclosed in the fourth full paragraph of column 1 of page 8589, the amplified fragment encoding the PAI-1₂₃ protein corresponds to nucleotides 444-999 of poPAI-1 and 238-793 of huPAI-1. These primers and corresponding location in the porcine and human genes have been incorporated by amendment into the '428 application and consist of the same material incorporated by reference of Mulligan-Kehoe et al. (2001) *supra* in the '428 application as originally filed.

I hereby declare that all statements herein of our own knowledge are true and that all statements made on information or belief are believed to be true; and further that these statements were made with the knowledge that willful statements and the like so made are punishable by fine or by imprisonment, or both under §1001 of Title 18 or the United States Code, and that such willful statements may jeopardize the validity of the application, any patent issuing there upon, or any patent to which this verified statement is directed.


Mary Jo Mulligan-Kehoe, Ph.D.

Date: 12/21/05

BEST AVAILABLE COPY